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ceived preventive treatment; 60.4% were on-demand treatment. Severe HB adults
reported significantly poorer HRQOL than the moderate subgroup mainly on phys-
ical components. No HRQOL difference was observed among children. The average
annual direct cost was €95,619 (SD 83,142) with no significant difference between
adults and children, but with a difference with severity status (3.3 times higher in
severe vs. moderate HB, p0.001). Substitutive therapy represented 90%, of the
total followed by hospitalizations 6.5%. Even if the prophylaxis strategy lead to
higher costs than an on-demand strategy (p0.001), it allows avoiding haemor-
rhagic events and remains in acceptable cost-effectiveness range. CONCLUSIONS:
To date, no economic burden of disease studies focusing only on HB have been
published. The EQOFIX study provides an important source of economic informa-
tion for health care payers.
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OBJECTIVES: The purpose of this study was to characterise the subjective experi-
ence of anaemic patients with CKD and specifically to identify a set of the most
salient symptoms and impacts associated with anaemia and iron supplementa-
tion, both in pre-dialysis and dialysis patients. METHODS: This was a cross-sec-
tional, semi-qualitative study in which one-on-one concept elicitation interviews
were conducted among CKD subjects treated with iron supplementation, alone or
in conjunction with erythropoiesis-stimulating agents (ESAs). The interviews were
audiotaped and transcribed for thematic content analysis. RESULTS: A total of 40
participants were included with median age 53 (range: 27-83 years) and 55% male.
Twenty-two of the participants were on dialysis and of those nearly all received
intravenous iron (91%) and ESAs (91%). Conversely, the majority of pre-dialysis
patients instead used oral iron (72%) while ESA use was less common (44%) in this
segment. Fatigue was the most frequently reported symptom related to anaemia
(83%). Other common symptoms included shortness of breath and itchiness. The
defining symptoms related to iron supplementation were gastrointestinal in na-
ture (abdominal pain, constipation, flatulence, bloating, nausea and vomiting).
These symptoms negatively affected mood and social activities (28%). A difference
between oral and intravenous iron was that the degree of bothersomeness from
nausea and gastrointestinal side effects was more pronounced in those receiving
iron tablets. Iron supplementation was specifically mentioned by some patients to
cause nausea and vomiting and thus interfering with keeping medication down. As
a result, iron supplementation side effects were severe enough to negatively affect
medication compliance. CONCLUSIONS: The results from this study highlight the
great burden anaemia of CKD can have on quality of life, social life and emotional
well-being. Alternative treatments that avoid the side effects of iron supplemen-
tation have the potential to substantially improve quality of life in this patient
population.
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OBJECTIVES:An observational study to investigate effectiveness and safety of anti-
TNF agents in treatment of moderate-to-severe psoriasis vulgaris was conducted in
25 centres from Turkey. This sub-analysis aimed to evaluate the results of work
productivity and activity impairment. METHODS: Patients (18 years) were fol-
lowed-up 24 weeks (visits at 4, 8, 16 and 24 week after baseline) and psoriasis area
and severity index (PASI), dermatology life quality index (DLQI) and work produc-
tivity and activity impairment (WPAI) questionnaires were completed. RESULTS:A
total of 86 patients (38.4% females, mean(standard deviation) age 42.8(13.5) years,
mean(SD) body mass index 29.5(16.2) kg/m2) with psoriasis vulgaris for mean(SD)
16.4 (8.7) years were included to the study. Of patients; 18.6%, 17.4% and 17.4% were
dyslipidemic, hypertensive and hyperglycaemic, respectively. Unemployment rate
among patients was 59% at baseline. The employed patients reported a median
(interquartile-range) 11(44)% absenteeism rate, 50(40)% presenteeism rate and
57(57)% work productivity loss at baseline and those decreased to median(IQR)
0(0)%, 0(20)% and 0(20)% at week 24, respectively (P0.001, P0.001 and P0.001,
respectively). Among all patients, median(IQR) activity impairment rate decreased
to 5(30)% at week 24 from 60(50)% at baseline (P0.001). Baseline median(IQR) PASI
score was 20(15) and decreased to 2(4) at week 24, whereas baseline median(IQR)
DLQI score was 16(10) and decreased to 1.5(7) at week 24 (P for both 0.001). The
reduction in PASI showed a moderate positive linear correlation with absenteeism,
presenteeism, work productivity and loss activity impairment rate (Rhos 0.47,
0.48, 0.45, 0.49, respectively, for all P0.05). CONCLUSIONS: Moderate-to-severe
psoriasis vulgaris seemed to cause high absenteeism, presenteeism, work produc-
tivity and loss activity impairment rates and anti-TNF agents significantly im-
proved work productivity and activity impairment. Anti-TNF agents also signifi-
cantly reduced PASI and DLQI scores and reduction in PASI was moderately
correlated with work productivity and activity impairment.
SYSTEMIC DISORDERS/CONDITIONS - Health Care Use & Policy Studies
PSY43
UTILIZATION OF PAIN MEDICATIONS IN PATIENTS WITH CHRONIC LOWER
BACK PAIN WHO INITIATED DULOXETINE OR STANDARD OF CARE FOR THE
MANAGEMENT OF PAIN
Peng X1, Wu N2, Chen SY2, Yu X2, Andrews JS1, Novick D3
1Eli Lilly and Company, Indianapolis, IN, USA, 2United BioSource Corporation, Lexington, MA,
USA, 3Eli Lilly and Company, Windlesham, Surrey, UK
OBJECTIVES: To describe pain medication use in patients with chronic lower back
pain (CLBP) after initiating duloxetine or standard of care (SOC) for pain
management. METHODS: Pharmacy and medical claims from SDI Health were
analyzed for adult patients with CLBP who initiated duloxetine or SOC (muscle
relaxants, gabapentin, pregabalin, venlafaxine, and tricyclic antidepressants) be-
tween 11/2010 and 4/2011. Treatment initiation was defined as no pill coverage for
duloxetine or SOC in previous 90 day. Included patients had no opioid use in 90
days before initiation. Propensity score matching was used to select patients with
similar baseline demographic and clinical characteristics for duloxetine and SOC
cohorts. Compliance to index medication was assessed via medication possession
ratio (MPR) and proportion of days covered (PDC) for 6 months after initiation.
Proportion receiving opioids and days on opioids after index date were assessed
and regression models were estimated to compare opioid use between cohorts.
RESULTS: 766 patients initiated duloxetine and 6,206 patients initiated SOC. After
matching, 743 patients were selected for the duloxetine (mean age: 57 years; fe-
male: 74%) and SOC (mean age: 57 years; female: 75%) cohorts, respectively. 92% of
duloxetine cohort started on or below recommended daily dose (60mg). Dulox-
etine cohort had significantly higher MPR (0.78 vs. 0.60) and PDC (0.50 vs. 0.31), were
less likely to use opioids (45% vs. 61%), and had fewer days on opioids (mean: 18 vs.
25) than SOC cohort (all p0.001). After adjusting for demographic and clinical
characteristics, duloxetine cohort initiated opioids later than SOC cohort (hazard
ratio: 0.76, 95% confidence interval: 0.65-0.88), and had fewer days on opioids (-6.9,
p0.001). CONCLUSIONS: CLBP patients initiating duloxetine had better compli-
ance to initiated medication and were less likely to use opioids than those initiating
SOC.
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OBJECTIVES: To evaluate the cost effectiveness of azacitidine treatment in com-
parison with Conventional Care Regimens (CCR), available in Greece. The analysis
is based on a National Health Service perspective.METHODS:A Markov model was
explored based on the Phase III randomized trial AZA-001, where patients were
analyzed over their lifetime. The health outcomes were estimated on:i) life years
(LY) gained and ii) Quality Adjusted Life Years (QALYs) gained. The cost outcomes
were the average direct costs associated with each MDS treatment arm (relating to
drugs and medications, monitoring, routine follow-up and adverse event manage-
ment). The cost effectiveness of azacitidine treatment, compared to BSC, LDC, and
SDC treatments, was based on the Incremental Cost Effectiveness Ratio (ICER). The
model was customized into the Greek Health Care Setting by launching a struc-
tured questionnaire addressed to Greek hematologists from 6 Hospitals. They pro-
vide information on the resource use for the management of blood product trans-
fusions and adverse events complications in Greece. RESULTS: The incremental
cost of treating the patients with azacitidine, compared to treating them with BSC
was €94,585. The incremental life years gained for azacitidine compared to BSC
were 2.63. The resulting incremental cost effectiveness ratio (cost per life year
gained) was €35,909 when comparing azacitidine with BSC. Equivalently, the ICER
of treating patients with azacitidine as compared with treating them with LDC or
SDC was €29,708 and €27,074 respectively. With regard to QALYs azacitidine is also
effective resulting in an additional 1.65 QALYs gained compared to BSC, 1.8 QALYs
compared to LDC, and 1.81 QALYs compared to SDC. .The corresponding ICERs
were €57,158, €47,791and €47,651 versus, BCD, LDC and SDC, respectively.
CONCLUSIONS: Azacitidine is a cost effective option for the treatment of Greek
MDS patients generating significant improvements in quality-adjusted survival.
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OBJECTIVES: The BURQOL-RD project is intended to develop a disease based model
capable of quantifying the socio-economic burden and Health-Related Quality of
Life (HRQOL) for patients with rare diseases (RD) and their caregivers in Europe.
Preliminary results from Spain are presented here. METHODS: On-line survey of
patients and carers afected by Cystic Fibrosis, Prader-Willi Syndrome, Haemo-
philia, Duchenne Muscular Dystrophy, Epidermolysis Bullosa, Fragile X Syndrome,
Sclerodermia, Mucopolysaccharidosis, Juvenile Idiopathic Arthritis or Histiocytosis
was launched in Spain through national patients organizations in September 2011
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